NEW YORK (GenomeWeb) – Epigenomics and its commercialization partner in China, BioChain, today said that Epigenomics' Epi proColon test has been included in China's screening guideline for colorectal cancer. 

Get the full story

This story is free
for registered users

Registering provides access to this and other free content.

Register now.

Already have an account?
Login Now.